Molecular Templates to Present at the UBS Global Healthcare Conference

AUSTIN, Texas, May 15, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq:MTEM) (“Molecular”), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer, today announced that its management will provide a corporate overview at the UBS Global Healthcare Conference, taking place May 21-23 at the Grand Hyatt New York hotel in New York City.

Presentation Details

Date: 
Time: 
Location:
Webcast:
Monday, May 21
8:00am Eastern Time
Ballroom IV
https://cc.talkpoint.com/ubsx001/052118a_as/?entity=70_OJGBE5X 

About Molecular Templates  

Molecular Templates is a clinical-stage oncology company focused on the discovery and development of differentiated, targeted, biologic therapeutics for cancer. We believe our proprietary biologic drug platform technology, referred to as engineered toxin bodies, or ETBs, provides a differentiated mechanism of action that may address some of the limitations associated with currently available cancer therapeutics. ETBs utilize a genetically engineered form of Shiga-like Toxin A subunit, or SLTA, a ribosome inactivating bacterial protein, that can be targeted to specifically destroy cancer cells.  Additional information about Molecular Templates can be obtained at http://www.mtem.com.

Investor Contact:
Andrew McDonald, Ph.D.
andrew@lifesciadvisors.com
646-597-6987

Adam Cutler
Chief Financial Officer
adam.cutler@mtem.com 
862-204-4006

Source: Molecular Templates, Inc.

Ads

You May Also Like

Biotech with Liquid Biopsy for Colorectal Cancer Secures $26 Million in New Funding

Clinical Genomics drives the commercialization of Colvera™, a liquid biopsy test service for colorectal ...

Mateon Announces Issuance of US Patent for Cathepsin Inhibition

SOUTH SAN FRANCISCO, Calif., Oct. 10, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), ...